URGN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

26.650

Open

26.410

VWAP

25.94

Vol

1.35M

Mkt Cap

1.28B

Low

24.570

Amount

34.92M

EV/EBITDA(TTM)

--

Total Shares

48.72M

EV

1.33B

EV/OCF(TTM)

--

P/S(TTM)

9.12

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Show More

Events Timeline

(ET)

2026-05-06

09:50:00

UroGen Q1 Revenue at $50.96M, Below Expectations

2026-03-30 (ET)

2026-03-30

09:10:00

UroGen Pharma Publishes Key Trial Results for Zusduri

2026-03-13 (ET)

2026-03-13

08:10:00

UroGen Pharma Grants Inducement RSUs to 11 New Employees

2026-03-02 (ET)

2026-03-02

08:10:00

UroGen Reports Q4 Revenue of $37.837M

2026-03-02

08:10:00

Jelmyto 2026 Net Product Sales Guidance at $97M to $101M

2026-03-02

08:00:00

UroGen Pharma Revises Loan Agreement for Up to $250M Financing

2026-02-27 (ET)

2026-02-27

08:40:00

UroGen Pharma ENVISION Trial Shows Zusduri Complete Response Rate of 83.9%

News

seekingalpha

05-06seekingalpha

PinnedUroGen Pharma Reports Strong Q1 2026 Earnings with Significant ZUSDURI Growth

seekingalpha

05-06seekingalpha

UroGen Pharma Q1 Earnings Beat Expectations

seekingalpha

05-05seekingalpha

UroGen Pharma to Announce Q1 Earnings on May 6

NASDAQ.COM

03-03NASDAQ.COM

UroGen Pharma Reports 2025 Financial Highlights

seekingalpha

03-02seekingalpha

UroGen Pharma Q4 2025 Earnings Call Highlights

NASDAQ.COM

03-02NASDAQ.COM

UroGen (URGN) Q4 2025 Earnings Call Transcript

4 Analyst Rating

Wall Street analysts forecast URGN stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

31.00

Averages

40.25

High

55.00

Current: 0.000

Low

31.00

Averages

40.25

High

55.00

Oppenheimer

Oppenheimer

Outperform

maintain

$34 -> $40

AI Analysis

2026-05-07

New

Reason

Oppenheimer

Oppenheimer

Price Target

$34 -> $40

AI Analysis

2026-05-07

New

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on UroGen Pharma to $40 from $34 and keeps an Outperform rating on the shares. Zusduri's Q1 sales of $29.2M vs. the firm/consensus estimates of $22.0M/19.6M together with key launch metrics show strong commercial inflection following the permanent J-code implementation on January 1, the firm says. Management described monthly growth in patient enrollment forms through the quarter with early Q2 maintaining the positive trend, adds Oppenheimer.

Jefferies

Amin Makarem

Buy

initiated

$40

2026-04-09

Reason

Jefferies

Amin Makarem

Price Target

$40

2026-04-09

initiated

Buy

Reason

Jefferies analyst Amin Makarem initiated coverage of UroGen Pharma with a Buy rating and $40 price target. The firm says the company's Zusduri has "strong" Phase 3 efficacy and durability data, positioning it as a a non-surgical alternative to repeat transurethral resection of bladder tumor in recurrent non-muscle invasive bladder cancer. Jefferies sees a favorable risk/reward for the shares, noting its survey suggests uptake should accelerate once payer frictions ease.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for URGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Urogen Pharma Ltd (URGN.O) is 0.00, compared to its 5-year average forward P/E of -4.29. For a more detailed relative valuation and DCF analysis to assess Urogen Pharma Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-4.29

Current PE

0.00

Overvalued PE

-1.33

Undervalued PE

-7.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-4.82

Current EV/EBITDA

-6.01

Overvalued EV/EBITDA

-0.58

Undervalued EV/EBITDA

-9.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.85

Current PS

2.79

Overvalued PS

5.23

Undervalued PS

2.47

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what is a good stock to buy into right now

Intellectia · 142 candidates

Market Cap: >= 1000.00MRegion: USPrice: >= $10.00Quarter Revenue Yoy Growth: >= 3.0%Analyst Consensus: Moderate Buy, Strong BuyRsi Category: moderateBeta: LowRisk, ModerateRisk, HighRisk, NegativeBetaMoving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

Arrowhead Pharmaceuticals Inc

10.49B

BROOKFIELD ASSET MANAGEMENT LTD

79.34B

Vir Biotechnology Inc

1.61B

Madrigal Pharmaceuticals Inc

11.58B

Sprott Inc

3.27B

Turning Point Brands Inc

1.57B

tomorrow’s top pick premarket

Intellectia · 6 candidates

Market Cap: >= 1000.00MRegion: USList Exchange: XNYS, XNAS, XASEOne Day Rise Prob: >= 60One Day Predict Return: >= 1.5%Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Kontoor Brands Inc

3.63B

Wix.Com Ltd

3.87B

Urogen Pharma Ltd

1.02B

Best Buy Co Inc

12.98B

Veeva Systems Inc

29.92B

CrowdStrike Holdings Inc

93.78B

Whales Holding URGN

Paradigm Biocapital Advisors LP

TCG Crossover Management, LLC

Jefferies Financial Group Inc.

Tang Capital Management, LLC

RTW Investments, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Urogen Pharma Ltd (URGN) stock price today?

The current price of URGN is 26.59 USD — it has increased 1.3

What is Urogen Pharma Ltd (URGN)'s business?

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

What is the price predicton of URGN Stock?

Wall Street analysts forecast URGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for URGN is40.25 USD with a low forecast of 31.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Urogen Pharma Ltd (URGN)'s revenue for the last quarter?

Urogen Pharma Ltd revenue for the last quarter amounts to 50.96M USD, increased 151.60

What is Urogen Pharma Ltd (URGN)'s earnings per share (EPS) for the last quarter?

Urogen Pharma Ltd. EPS for the last quarter amounts to -0.47 USD, decreased -48.91

How many employees does Urogen Pharma Ltd (URGN). have?

Urogen Pharma Ltd (URGN) has 291 emplpoyees as of May 08 2026.

What is Urogen Pharma Ltd (URGN) market cap?

Today URGN has the market capitalization of 1.28B USD.